News | September 17, 2010

German Company Reports First-in-Man Transcatheter Aortic Valve

September 17, 2010 - An aortic valve has been successfully implanted in the acute porcine model by Transcatheter Technologies GmbH (TT) using its Trinity system.

The acute in vivo study of the system has shown:

• Accurate stepwise positioning of Trinity via an antegrade transapical approach.
• Full expansion and anchoring of the Trinity valve prosthesis before the refolding of the stent.
• Complete evaluation of the fully expanded prosthesis’ function before refolding and repositioning or retrieval.
• Detachment of the stent from the catheter without changing the geometry of the deployed valve prosthesis.
• Outstanding anchoring and sealing due to the design of the stent.
• Low transvalvular gradients.

TT’s true repositioning system allows for complete expansion of the valved stent and full evaluation of prosthesis' function before repositioning, before retrieval and before final release.

“Trinity protects the fragile valve leaflets by Zero Pressure Crimping. This prevents crushing and damaging of the leaflets when the frame is folded. We expect that this will increase the lifespan of the valve prosthesis and thereby allow for implantation in even younger patients,” commented Wolfgang Goetz, M.D., Ph.D., CEO. “Our animal trials validate the feasibility of the technology in vivo. We are very proud to have achieved this significant milestone within a very short period of time.”

Transcatheter Technologies successfully closed the seed financing round in 2009 with High-Tech Gründerfonds and Seedfonds Bayern. The investment will be used for the development of a novel biological heart valve up to the proof of concept.

“Transcatheter Technologies’ valve design can solve major problems of common prosthesis. Thereby, valve implantations become an option for currently untreatable patients,” said Dr. Michael Nettersheim, of High-Tech Gründerfonds. “We are convinced that the medicinal as well as technological expertise of the team provide an ideal base for a successful corporate development.”

For more information: www.high-tech-gruenderfonds.de

Related Content

Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology| January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology| January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology| November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology| November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology| November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Videos | Heart Valve Technology| November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Harpoon Mitral Valve Repair System data reported at TCT 2017
Feature | Heart Valve Technology| November 07, 2017
November 7, 2017 – A new study has found that a pioneering device to repair heart valves is safe and effective, and c
Videos | Heart Valve Technology| November 07, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, explains the current state o
Overlay Init